Editing Anticoagulant (section)

====Direct factor Xa inhibitors====
{{main|Direct Xa inhibitor}}
Drugs such as [[rivaroxaban]], [[apixaban]] and [[edoxaban]] work by inhibiting factor Xa directly (unlike heparins and fondaparinux, which work via antithrombin activation).
Also included in this category are [[betrixaban]] from Portola Pharmaceuticals, the discontinued [[darexaban]] (YM150) from Astellas, and, more recently,  the discontinued [[letaxaban]] (TAK-442) from Takeda and [[eribaxaban]] (PD0348292) from Pfizer.
Betrixaban is significant as it was in 2018, the only oral factor Xa inhibitor approved by the FDA for use in acutely medically ill patients.<ref>{{cite journal | vauthors = Lekura J, Kalus JS | title = Overview of betrixaban and its role in clinical practice | journal = American Journal of Health-System Pharmacy | volume = 75 | issue = 15 | pages = 1095–1102 | date = August 2018 | pmid = 29941506 | doi = 10.2146/ajhp170785 | s2cid = 49418996 }}</ref> Darexaban development was discontinued in September 2011; in a trial for prevention of recurrences of myocardial infarction in addition to dual antiplatelet therapy (DAPT), the drug did not demonstrate effectiveness, and the risk of bleeding was increased by approximately 300%.<ref name="Steg">{{cite journal | vauthors = Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB | title = RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome | journal = European Heart Journal | volume = 32 | issue = 20 | pages = 2541–54 | date = October 2011 | pmid = 21878434 | pmc = 3295208 | doi = 10.1093/eurheartj/ehr334 }}</ref> The development of letaxaban for acute coronary syndrome was discontinued in May 2011 following negative results from a Phase II study.<ref>{{cite web | first1 = Joseph | last1 = Dwyer | first2 = Conor | last2 = Walsh | title = First Time European Approval for Xarelto in ACS | publisher = Decision Resources | date = May 2013 | url = http://decisionresources.com/The-Decision-Resources-Blog/May-2013/European-Approval-for-Xarelto-in-ACS-052913 | archive-url = https://web.archive.org/web/20140719173801/http://decisionresources.com/The-Decision-Resources-Blog/May-2013/European-Approval-for-Xarelto-in-ACS-052913 | archive-date=2014-07-19 }}</ref>